SEC Form 4 · accession 0000899243-18-030793
Akebia Therapeutics, Inc. · AKBA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michel Dahan
Officer — SVP, Chief Business Officer
Period of report
Dec 12, 2018
Accepted (ET)
Dec 13, 2018 · 8:14 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001517022
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Dec 12, 2018 | F | 23,385 | $8.94 | D | 93,841 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Includes 2,000 shares of common stock inadvertently omitted from the reporting person's Form 3 filed on March 18, 2016.